The state of Oklahoma currently has 7 active clinical trials seeking participants for Head and Neck Cancer research studies. These trials are conducted in various cities, including Oklahoma City, Tulsa, Norman and Edmond.
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
NCT05850663
Recruiting
The purpose of this study is to examine the uses of a mobile health-based assessment and symptom monitoring platform.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Head and Neck Cancer
Register for Updates
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
NCT03972527
Recruiting
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving radiation therapy with or without concurrent chemotherapy.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/11/2024
Locations: Oklahoma Cancer Specialtists and Research Intstitute, Tulsa, Oklahoma
Conditions: Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
Register for Updates
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859
Recruiting
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Esophageal Cancer, Ovarian Cancer, Endometrial Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Non-small Cell Lung (NSCLC), Urothelial Cancer
Register for Updates
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
NCT05704985
Recruiting
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.
Gender:
All
Ages:
12 years and above
Trial Updated:
02/07/2024
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
Register for Updates
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
NCT04373642
Recruiting
The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Head and Neck Cancer
Register for Updates
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab Learn more about the side effects of BT5528 Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSC... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Stephenson Cancer Center (Oklahoma University), Oklahoma City, Oklahoma
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates